Happy holidays from our global team!
Mirum Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
Foster City, CA 35,883 followers
Creating transformative medicine for people with rare liver disease.
About us
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX). Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.
- Website
-
https://mirumpharma.com/
External link for Mirum Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Foster City, CA
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
989 E Hillsdale Blvd.
Suite 300
Foster City, CA 94404, US
Employees at Mirum Pharmaceuticals, Inc.
Updates
-
We’re excited about the growth Mirum has achieved since its inception in 2018 and to see that progress recognized by Forbes as one of America’s Most Successful Mid-Cap Companies for 2025. This recognition celebrates the hard work of our global team, our commitment to rare disease, and the continued mission-driven growth of the company. #ForbesMidCap #Mirumpharma #RareDisease
Introducing America's Most Successful Mid-Cap Companies 2025: The top 100 ranking is based on earnings growth, sales growth, return on equity and total stock return for the last five years, with more weight given to the latest year’s data in the ranking. All data is as of November 27, 2024. SEE LIST: https://trib.al/eXwyaMq
-
-
This season of thanks reminds us of the many reasons we are grateful. From the remarkable rare disease community, advocates, and clinicians to the love of family, friends, and even our pets—we could not be more thankful. What are you most thankful for this year? Share with us in the comments! #gratitude #thankfultogether #rarediseasecommunity
-
Thanks to all who attended our presentations at #TLM2024 throughout the weekend. We had a great time catching up with many faces old and new, and learning about the exciting advancements in liver disease. If you would like to learn more about the data presented, visit our Publications & Presentations page. https://lnkd.in/g4d4_p39
-
-
As we gear up for the final day of #TLM2024, we hope you’ll join us for Poster Session IV in Poster Hall C tomorrow from 1:00-2:00 pm PT for our late-breaker poster presentation and many more. See you there! #RareDisease
-
-
Day one of AASLD #TLM2024 has been a success! We are excited for another impactful day—join us tomorrow for an oral presentation and fireside discussion! Hope to see you there. #RareDisease
-
-
We are gearing up to attend #TLM24 AASLD The Liver Meeting ® and are honored to celebrate 75 years of AASLD alongside healthcare providers, industry colleagues, patient advocates, and many more. We look forward to seeing many of you in person and hope you’ll visit us at booth 839!
-
-
Today, we reported third quarter 2024 financial results. Tune in at 8:30 a.m. ET/5:30 a.m. PT to hear a business update from our executive team. Listen to the webcast: https://bit.ly/3Cl4Q6R Read the press release: https://bit.ly/3UOY3J7 #financialresults #thirdquarter
-
-
This #VeteransDay, we salute our country's heroes for their time and service in the US military. Today, Benjamin M., Regional Account Manager, shares firsthand how influential his military service has been in his life, specifically in his professional life. To Ben and all our nation's veterans, THANK YOU.
-
-
This weekend, during #NASPGHAN2024, data from our clinical studies were presented. Interested in learning more? Visit our Publications & Presentations section on mirumpharma.com to read the full analyses presented during NASPGHAN. https://bit.ly/3CgrNVx
-